Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of Huntington's disease
3.2.1.2 Increased research and development activities related to Huntington's disease
3.2.1.3 Growing awareness related to the disease
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited availability of effective treatment
3.2.2.2 Stringent regulatory requirement
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drugs, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Tetrabenazine
5.3 Deutetrabenazine
5.4 Other drugs
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Branded
6.3 Generic
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Bausch Health Companies Inc.
9.2 CHEPLAPHARM Arzneimittel GmbH
9.3 Dr. Reddy’s Laboratories Ltd.
9.4 H. Lundbeck A/S
9.5 Hikma Pharmaceuticals PLC
9.6 Lupin Limited
9.7 Neurocrine Biosciences, Inc.
9.8 Sun Pharmaceutical Industries Ltd.
9.9 Teva Pharmaceutical Industries Ltd.
9.10 Upsher-Smith Laboratories, LLC.
